175 related articles for article (PubMed ID: 9456190)
1. Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity.
Maini CL; Sciuto R; Ferraironi A; Vici P; Tofani A; Festa A; Conti F; Lopez M
J Nucl Cardiol; 1997; 4(6):502-8. PubMed ID: 9456190
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction.
Valdés Olmos RA; ten Bokkel Huinink WW; ten Hoeve RF; van Tinteren H; Bruning PF; van Vlies B; Hoefnagel CA
Ann Oncol; 1994 Sep; 5(7):617-22. PubMed ID: 7993837
[TBL] [Abstract][Full Text] [Related]
3. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.
Estorch M; Carrió I; Martínez-Duncker D; Berná L; Torres G; Alonso C; Ojeda B
J Clin Oncol; 1993 Jul; 11(7):1264-8. PubMed ID: 8315423
[TBL] [Abstract][Full Text] [Related]
4. High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction.
Valdés Olmos RA; Carrió I; Hoefnagel CA; Estorch M; ten Bokkel Huinink WW; López-Pousa J; Dalesio O
Nucl Med Commun; 2002 Sep; 23(9):871-7. PubMed ID: 12195092
[TBL] [Abstract][Full Text] [Related]
5. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
6. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
Lopez M; Vici P; Di Lauro K; Conti F; Paoletti G; Ferraironi A; Sciuto R; Giannarelli D; Maini CL
J Clin Oncol; 1998 Jan; 16(1):86-92. PubMed ID: 9440727
[TBL] [Abstract][Full Text] [Related]
7. Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure.
Schaadt B; Kelbaek H
J Nucl Cardiol; 1997; 4(6):494-501. PubMed ID: 9456189
[TBL] [Abstract][Full Text] [Related]
8. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography.
Cottin Y; Touzery C; Dalloz F; Coudert B; Toubeau M; Riedinger A; Louis P; Wolf JE; Brunotte F
Clin Cardiol; 1998 Sep; 21(9):665-70. PubMed ID: 9755384
[TBL] [Abstract][Full Text] [Related]
9. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
Jensen BV; Skovsgaard T; Nielsen SL
Ann Oncol; 2002 May; 13(5):699-709. PubMed ID: 12075737
[TBL] [Abstract][Full Text] [Related]
10. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children.
Kremer LC; Tiel-van Buul MM; Ubbink MC; Offringa M; Ottenkamp J; Olmos RV; Voûte PA
J Clin Oncol; 1999 Apr; 17(4):1208. PubMed ID: 10561180
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of echocardiography and acoustic cardiography to monitor patients undergoing anthracycline chemotherapy.
Toggweiler S; Odermatt Y; Brauchlin A; Zander T; Müller A; Zuber M; Winterhalder R; Erne P
Clin Cardiol; 2013 Apr; 36(4):201-6. PubMed ID: 23161530
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
13. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.
Basser RL; Abraham R; To LB; Fox RM; Green MD
Ann Oncol; 1999 Jan; 10(1):53-8. PubMed ID: 10076722
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
15. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.
Estorch M; Carrió I; Berná L; Martínez-Duncker C; Alonso C; Germá JR; Ojeda B
J Nucl Med; 1990 Dec; 31(12):1965-9. PubMed ID: 2266394
[TBL] [Abstract][Full Text] [Related]
16. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity.
Carrió I; Estorch M; Berná L; López-Pousa J; Tabernero J; Torres G
J Nucl Med; 1995 Nov; 36(11):2044-9. PubMed ID: 7472595
[TBL] [Abstract][Full Text] [Related]
17. Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment.
Vici P; Ferraironi A; Di Lauro L; Carpano S; Conti F; Belli F; Paoletti G; Maini CL; Lopez M
Clin Ter; 1998; 149(921):15-20. PubMed ID: 9621483
[TBL] [Abstract][Full Text] [Related]
18. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
19. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
20. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
